BIVI: Don’t Miss BioVie’s KOL Event on Parkinson’s Breakthrough!

Company & KOL Event Overview

BioVie Inc. (NASDAQ: BIVI) is a micro-cap, clinical-stage biotech developing therapies for neurodegenerative and chronic diseases (investors.bioviepharma.com). Its lead candidate bezisterim (NE3107) targets neuroinflammation and insulin resistance—key drivers of Alzheimer’s and Parkinson’s pathology (www.biospace.com). BioVie has announced a virtual Key Opinion Leader (KOL) event on May 7, 2026 to discuss how bezisterim’s mechanism could address Parkinson’s disease progression, ahead of Phase 2 trial topline results expected in Q2 2026 (www.biospace.com) (www.biospace.com). This event is a critical catalyst for the company, as positive Phase 2 data could signal a potential breakthrough in Parkinson’s treatment. Investors are watching closely, since bezisterim, an oral anti-inflammatory/insulin-sensitizer, aims to modify disease course rather than just symptoms – something rarely achieved in Parkinson’s (www.biospace.com). Given BioVie’s small market valuation and lack of current revenues, any encouraging news from the KOL event or upcoming trial results could have an outsized impact on the stock.

$5,578.90 +1.10%

March 31 — First Notice Day is approaching. Claim your briefing to learn how to position for the delivery shock.

Reserve My Report

Dividend Policy & Shareholder Returns

BioVie has never paid a dividend, and it does not anticipate any cash dividends in the foreseeable future (www.otcmarkets.com). As an early-stage biotech with no approved products or profits, the company retains all capital to fund R&D and operations. Investors in BIVI must seek returns through stock price appreciation, as the only potential “return” on shares will come from selling the stock at a higher price in the future (www.otcmarkets.com) (www.otcmarkets.com). This policy is typical for development-stage biotechs – cash is devoted to advancing drug candidates rather than paying dividends.

Financial Position, Leverage & Debt Maturities

BioVie’s financials reflect its pre-revenue, R&D-focused status. The company has generated no revenues to date and does not expect revenue until it can achieve FDA approval for a product (www.otcmarkets.com). As of its last fiscal year (June 30, 2025), BioVie had cash and equivalents of about $17.5 million on the balance sheet (www.otcmarkets.com). This cash balance was bolstered by periodic capital raises (detailed below) and even a non-dilutive grant. Notably, in April 2024 BioVie secured a $13.1 million U.S. Department of Defense grant to fully fund a Phase 2 trial of NE3107 in long-COVID (the ADDRESS-LC study) (www.otcmarkets.com) (www.otcmarkets.com). This grant financing for the long-COVID program helps preserve BioVie’s cash for its Parkinson’s and Alzheimer’s programs.

🔒
Insider-Style Access — No Accreditation Needed
Dr. Mark Skousen reveals a five-letter access code to invest alongside a Wall Street legend who controls a large private stake in SpaceX.
Minimums from $500 on public fund options • Limited private slots

Importantly, BioVie carries minimal debt as of 2025. The company had taken on a venture term loan in late 2021, but it fully repaid the $15 million loan upon its maturity on December 1, 2024, including a final $0.85 million fee, which released all liens on BioVie’s assets (www.otcmarkets.com). That payoff eliminated the only significant debt on the balance sheet. With the loan gone, BioVie’s leverage is very low and no significant debt maturities loom. Consequently, interest expense has dropped (total interest on that loan was only ~$0.3 million in FY2025) and coverage ratios are not meaningful, since BioVie now has no interest-bearing debt and continues to operate at a net loss (www.otcmarkets.com) (www.otcmarkets.com). The absence of debt gives BioVie some balance sheet flexibility, but it also means the company relies heavily on equity financing to fund its pipeline.

Funding, Dilution & Share Count Changes

To finance its R&D and clinical trials, BioVie has repeatedly tapped equity markets, resulting in substantial dilution of shareholders. In March 2024, BioVie raised gross proceeds of $21 million in a best-efforts public offering by issuing 15,000,000 new shares (along with warrants on 10.5 million shares) at $1.00 per share/unit (www.biospace.com). Later that year, the company conducted two smaller offerings: in September 2024 it sold ~1.96 million shares (and prefunded warrants) at $1.53 per share, raising ~$3.0 million (investors.bioviepharma.com); and in October 2024 it issued 1.15 million shares at $2.83 in a direct offering for ~$3.2 million (www.biospace.com). These frequent issuances significantly increased the outstanding share count and even necessitated a reverse stock split to maintain Nasdaq listing compliance (as evidenced by BioVie’s stock price jumping from ~$1+ to over $30 in late 2024 after a share consolidation) (www.otcmarkets.com).

7T
Breaking: April 29 — The Big Reveal
Get the Gray Swan’s insider dossier before the public announcement.

Get Access

Dilution continued into 2025: in August 2025, BioVie closed a $12 million underwritten public offering, selling 6,000,000 units at $2.00 each (each unit including one share plus one five-year warrant exercisable at $2.50) (investors.bioviepharma.com) (investors.bioviepharma.com). The result of these financings is that BioVie’s share count has ballooned (current shares outstanding are roughly 7.5 million), while existing shareholders have seen their ownership percentages decrease. On a positive note, the Department of Defense grant mentioned earlier was nondilutive funding that saved the company from raising an additional ~$13 million via equity (www.otcmarkets.com). Nonetheless, investors should expect that further capital will be needed. BioVie openly acknowledges it will likely finance future needs through additional equity or debt raises or partnerships until it can commercialize a product (www.otcmarkets.com). This overhang of potential dilution is a constant consideration for BIVI shareholders.

Valuation and Comparables

BioVie’s current market valuation is extremely modest, reflecting both the early-stage risk of its drug programs and the dilutive impact of past financing. At a recent stock price around $1.40–1.50, BioVie’s market capitalization is only on the order of $10–15 million (ycharts.com). This is tiny both in absolute terms and relative to the approximately $352 million accumulated deficit the company has racked up developing its pipeline (www.otcmarkets.com). In other words, investors are valuing BioVie at only a few cents on each dollar spent historically – a sign of high skepticism about ultimate success. Traditional valuation metrics are not applicable: BioVie has no earnings (P/E is negative) and no product revenue, so one cannot use price/sales or PEG ratios. Even Price-to-Book is low; with stockholders’ equity around $19–20 million (www.otcmarkets.com), the stock trades below book value (roughly ~0.5x P/B). The enterprise value (EV), after subtracting cash on hand (likely around the same magnitude as the market cap), is perhaps only a few million dollars – implying the market assigns very little value to BioVie’s drug assets at present.

For context, other biotech companies with Phase 2/3 neurodegenerative programs often have market caps in the hundreds of millions. BioVie’s ultra-low valuation suggests the market has written off a high probability of failure or further dilution. Should BioVie’s trials succeed, however, the upside revaluation could be significant, given the multi-billion-dollar market potentials of Alzheimer’s or Parkinson’s therapies. In essence, BIVI stock is priced as a binary option on clinical outcomes: very low valuation now, with substantial potential if its drug candidates prove effective (and conversely, risk of near-worthlessness if they fail).

Pipeline Highlights and Upcoming Catalysts

BioVie’s pipeline currently centers on bezisterim (NE3107) for multiple neurological indications, and a separate liver disease program:

Parkinson’s Disease (Phase 2) – The SUNRISE-PD trial is a Phase 2 study of bezisterim in early Parkinson’s patients. It completed enrollment of newly diagnosed, untreated patients to test if NE3107 can improve disease signs and alter biomarkers of disease progression (www.globenewswire.com). Top-line data are expected in Q2 2026, and the May 7, 2026 KOL event will update on trial progress and bezisterim’s mechanism (www.biospace.com) (www.biospace.com). Positive results here could pave the way for a Phase 3 and position bezisterim as a disease-modifying PD therapy – a potential game-changer in a field dominated by symptomatic treatments.

Alzheimer’s Disease (Phase 3 completed) – BioVie ran a Phase 3 trial of NE3107 in mild-to-moderate Alzheimer’s, which read out in late 2023. Unfortunately, this trial was marred by Good Clinical Practice (GCP) violations at multiple sites, leading to a majority of patients’ data being excluded from the efficacy analysis (www.pharmaceutical-technology.com). In a subset of 57 “per-protocol” patients, NE3107 showed positive trends in cognitive and functional measures, and improvements in inflammation and metabolic biomarkers (investors.bioviepharma.com) (www.pharmaceutical-technology.com). However, because so many participants were disqualified, the results were not robust enough to declare a clear success. BioVie has presented these findings (e.g., at the AD/PD 2024 conference) and noted that NE3107 appeared biologically active and safe, but acknowledged that a confirmatory trial will be needed (www.pharmaceutical-technology.com). It remains an open question how – or if – BioVie will advance NE3107 in Alzheimer’s. A full new Phase 3 trial would be expensive, so management may seek a partnership or other strategic options once the Parkinson’s data are in hand.

Long COVID (Phase 2) – The ADDRESS-LC trial is testing NE3107 in patients suffering cognitive impairment and fatigue due to long COVID (www.otcmarkets.com). This study is entirely funded by a Department of Defense grant (www.otcmarkets.com), which underscores the government’s interest in long COVID solutions. It also means BioVie can pursue this indication without draining its own cash. The trial was authorized in 2024 (www.otcmarkets.com) and is likely underway; any data (possibly in late 2026) could reveal if NE3107’s anti-inflammatory benefits extend to post-viral neurologic syndromes.

Ascites/Liver Cirrhosis (Phase 3 ready) – BioVie’s legacy program is BIV201 (continuous infusion terlipressin) for refractory ascites in advanced liver cirrhosis. BIV201 has Orphan Drug and Fast Track designations and showed promise in Phase 2, but BioVie halted internal work on it in 2024 because a Phase 3 would take two+ years and significant capital (www.fiercebiotech.com). Instead, BioVie is spinning out this program into a new company, “Option Therapeutics,” via an IPO (www.fiercebiotech.com). In March 2026 BioVie filed for Option Therapeutics to raise ~$17–20 million, after which BioVie would still own about 60% of the spin-out (www.fiercebiotech.com) (www.fiercebiotech.com). This structure allows the ascites drug to be advanced with dedicated funding, while BioVie’s main focus and resources remain on NE3107. The Option Therapeutics IPO (if successful) is a catalyst to watch: it could unlock value for BioVie shareholders (who indirectly hold a stake in Option via BioVie) and relieve BioVie from having to fund the costly ascites Phase 3 itself.

In the near term, the biggest catalyst is the Parkinson’s Phase 2 data. BioVie’s KOL event suggests management is optimistic about NE3107’s potential in PD. Any clear clinical efficacy signal – for example, improved motor function or biomarker changes indicating slowed disease progression – would be transformative for the company’s outlook. Positive PD results could also validate NE3107’s mechanism of reducing neuroinflammation, which might read through to Alzheimer’s and long COVID as well. Conversely, disappointing PD results would cast doubt on the entire NE3107 platform.

Risks, Red Flags, and Open Questions

Despite the exciting potential of a breakthrough Parkinson’s therapy, BioVie comes with significant risks and uncertainties:

No Revenue & Ongoing Losses: BioVie is not yet generating any revenue and has a history of operating losses, with an accumulated deficit exceeding $350 million (www.otcmarkets.com). It will continue to burn cash for the foreseeable future. The company will need substantial additional financing to fund operations and any Phase 3 trials. This raises the risk of further dilution or debt if partnerships are not secured. BioVie has openly stated that until it can commercialize a product, it will rely on public or private financings or collaborations to raise capital (www.otcmarkets.com).

Dilution & Shareholder Dilution: Past financings have dramatically diluted shareholders (e.g., tens of millions of shares issued in 2024-25, followed by reverse splits). With a market cap only around $10–15M currently (ycharts.com), issuing even a few million new shares to raise cash could spike the share count and pressure the stock price. There is a risk of a vicious cycle if the stock remains very low-priced – BioVie might have to do another reverse split or struggle to stay Nasdaq-listed if shares trade below $1 for too long. Investors should be prepared for the likelihood of additional equity raises in 2026/27 unless a larger partner provides funding.

Clinical and Regulatory Risk: All of BioVie’s drug candidates are in trials and may fail to demonstrate safety or efficacy at any stage. The Alzheimer’s Phase 3 outcome is a cautionary tale: protocol violations at trial sites led to invalid data, undermining what had been hoped to be a pivotal study (www.pharmaceutical-technology.com). Although BioVie blamed scientific misconduct at certain sites for the failed trial, the fact remains that the trial did not conclusively meet its endpoints. This has delayed any FDA filing for NE3107 in Alzheimer’s by years (if it happens at all). For Parkinson’s, the current Phase 2 is smaller and earlier – positive indications would need to be confirmed in a larger Phase 3. There is no guarantee NE3107 will replicate any effects in a broader patient population. Additionally, the long COVID trial outcome is uncertain, and the ascites program, while promising, must navigate FDA approval via the spin-out. Drug development in these indications is inherently high-risk, and any trial failure or safety issue could severely impact BioVie’s prospects.

Litigation and Management Credibility: The irregularities in the Alzheimer’s trial have not only scientific implications but also legal ones. BioVie is facing consolidated securities class-action litigation (and related shareholder derivative suits) alleging that the company and certain officers misled investors regarding trial conduct and GCP compliance (www.otcmarkets.com) (www.otcmarkets.com). The class action (In re BioVie Inc. Securities Litigation) covers investors who bought during Dec 2022–Nov 2023, essentially claiming BioVie painted an overly rosy picture of its Phase 3 trial when in reality the data was compromised. BioVie “believes the claims are without merit” (www.otcmarkets.com), but resolving these lawsuits will cost time and money, and they underscore concerns about management’s credibility and oversight. New or prospective investors will be keen to see improved trial execution going forward. Any further missteps could deal irreparable damage to BioVie’s reputation.

Liquidity & Going Concern: With such a small market cap and limited cash on hand, BioVie runs the risk of a going-concern issue if it cannot raise capital on reasonable terms. The company’s future truly hinges on the next catalysts. A successful Parkinson’s Phase 2 could open doors to partnering with a larger pharma or raise money at a higher stock price. But a failure might leave BioVie with dwindling cash and little investor appetite for another dilutive financing. The recent plan to spin off Option Therapeutics is an innovative way to fund the ascites program, but that IPO itself is not guaranteed to succeed in a volatile biotech market. If the Option IPO fails or markets sour, BioVie might have to find alternative funding or shelve that program.

Valuation Disconnect & Upside Risk: Paradoxically, one “risk” for skeptics is the upside scenario. BioVie’s ultra-low valuation means even modest good news can spike the stock sharply. For example, any compelling efficacy signal from the SUNRISE-PD trial or even optimistic language at the KOL event could cause a rapid re-rating of BIVI shares. Short sellers or those expecting a collapse risk getting caught if BioVie delivers unexpectedly strong data. That said, such upside is contingent on scientific success, which remains an open question.

Open questions that remain include: Will bezisterim’s Phase 2 data actually demonstrate disease-modifying effects in Parkinson’s patients? If so, how soon can BioVie move to Phase 3, and can it secure a partner or funding to do so? What is the fate of the Alzheimer’s program? – Will BioVie design a new trial (perhaps focusing on a biomarker-enriched subset) or seek a partnership to share the cost, or even abandon AD to focus on PD? Additionally, how will the Option Therapeutics spin-out play out? BioVie expects to retain a majority stake (www.fiercebiotech.com), but will public investors be interested in funding the ascites drug via this IPO, and might BioVie itself need to contribute capital to Option if the IPO pricing is weak? Lastly, can BioVie avoid further dilutive financings before major data readouts? The company’s cash runway is not clearly disclosed, but given the burn rate (~$17.5M net loss in FY2025) (www.otcmarkets.com), the clock is ticking. All these questions highlight that BioVie is at a pivotal juncture.

Conclusion

BioVie offers a high-risk, high-reward profile. The upcoming KOL event on May 7th will be a key moment for management to articulate bezisterim’s potential and set expectations for the Parkinson’s trial results. Investors shouldn’t miss this event, as it may provide clues to the data and the company’s strategy. With a novel mechanism targeting inflammation and insulin resistance, BioVie’s approach to neurodegenerative diseases sets it apart and could be a breakthrough if successful. However, the company’s past hurdles – from trial conduct issues to heavy dilution – serve as reminders to exercise caution. BIVI is essentially a bet on the science: a bet that NE3107 can succeed where others have failed, and that BioVie’s tiny base can grow into something much larger. For those who can tolerate the volatility and binary nature of biotech outcomes, BioVie’s current low valuation could be an opportunity ahead of major clinical news. But for now, the company has everything to prove at this upcoming Parkinson’s readout and beyond. In summary, don’t miss BioVie’s KOL event – it could mark the beginning of a turnaround for this embattled biotech, or reinforce the challenges it faces on the road to a true breakthrough.

Sources: BioVie Inc. investor disclosures, SEC filings, and press releases (www.biospace.com) (www.otcmarkets.com) (www.biospace.com) (investors.bioviepharma.com); YCharts market data (ycharts.com); Pharmaceutical industry analyses (www.pharmaceutical-technology.com); and BioVie’s 10-K risk factor statements (www.otcmarkets.com) (www.otcmarkets.com).

For informational purposes only; not investment advice.

$2 EV Stock No One's Talking About

This company is a sneaky EV play that no one’s talking about. They’re producing an odd variation on the traditional EV that has consumers raving.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

$30 Stock Freaking Out Billionaires

This stock is an industry leader in a robotics technology that is freaking out billionaires (trading for just $30).

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

The Best TaaS Stock Right Now

This company is set to corner the market in a self-driving technology that  could fundamentally change our entire society – much like the internet did.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

Up to 20,000 IPOs All in One Day

A radical $2.1 quadrillion shift is coming to the financial markets.

Some are calling it G.T.E. and Mark Cuban, Elon Musk, Richard Branson, and even banks like J.P. Morgan are invested in the tech behind it.

Just $25 could get you in alongside these billionaires. 

Enter your email address to receive the video that reveals it all.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works

53-cent Biotech Stock with $2 Price Target

Steve Cohen, the billionaire stock picker known for running one of the most successful hedge funds ever, has poured millions into the first stock, and it’s trading for only 53 cents.

Enter your email address to receive this company’s name and ticker symbol for free.



By submitting your email address, you give Stock Market Junkie permission to deliver the report or research you’re requesting to your email inbox. As a bonus, you will also get a free subscription to one of our carefully selected marketing partners. You can unsubscribe at any time. To review our privacy policy, click here: Privacy Policy | How it Works